Psyence BioMed and PsyLabs Achieve Major Milestone in High-Purity Ibogaine Production
DENVER, Colo., Jul 31, 2025 (247marketnews.com)- Psyence Biomedical (NASDAQ:PBM) reported that its strategic partner, PsyLabs, produced a GMP-aligned Ibogaine Total Alkaloid (TA) extract that meets all microbial safety standards for food-grade consumption, as confirmed by an accredited third-party laboratory.
This breakthrough reflects the growing impact of Psyence BioMed’s continued investment in PsyLabs, following its initial equity acquisition in 2024 and further investment in 2025. The collaboration supports PsyLabs’ mission to develop scalable, compliant, and globally relevant psychedelic active pharmaceutical ingredients (APIs).
Tony Budden, CEO of PsyLabs, stated, “We are committed to refining our processes to achieve even higher purity levels, supporting the growing demand for high-quality psychedelic APIs.”
PsyLabs is actively expanding its extraction and chemistry capabilities to meet increasing global demand for high-purity compounds, including Ibogaine HCl, Psilocybin Isolate, and other 90%+ purity SKUs derived from Iboga and mushrooms.
PsyLabs’ Ibogaine extract will be made available to licensed research institutions and therapeutic developers worldwide, ensuring a consistent, ethically sourced, and quality-assured supply for clinical and scientific use.
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com